Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
| ▸ | USP9X | Q93008 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26964497 | 1.00 | HTR6 (0.33) | HTR6CARM1ADRA1AALDH1A1IDH1 | |
| SCHEMBL30925441 | 0.80 | ALDH1A1 (0.37) | HTR6CARM1ADRA1AALDH1A1 | |
| SCHEMBL30925478 | 0.79 | CARM1 (0.34) | HTR6CARM1ADRA1AALDH1A1USP9X | |
| SCHEMBL30925503 | 0.77 | SLC40A1 (0.39) | HTR6ADRA1AALDH1A1 | |
| SCHEMBL30925540 | 0.74 | HTR6 (0.36) | HTR6ADRA1AALDH1A1 | |
| SCHEMBL27214171 | 0.71 | GLO1 (0.57) | ALDH1A1 | |
| SCHEMBL30925431 | 0.71 | GLO1 (0.57) | ALDH1A1 | |
| SCHEMBL25773406 | 0.69 | KCNH2 (0.33) | USP9X | |
| SCHEMBL30925408 | 0.68 | ALDH1A1 (0.40) | HTR6ADRA1AALDH1A1 | |
| SCHEMBL30925495 | 0.67 | TDP1 (0.52) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ZOETIS LLC | 2024-05-09 | — | — | US | disclosed |
| CN-116806218-A | Sulfonamide and its use for the treatment of parasitic helminth infections and diseases | 新基公司 | 2023-09-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ARSA, MRPS2, SULT2A1 | HTR6 3742/4885CARM1 938/4885ADRA1A 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.